Microarray Core

基因组学核心的作用是支持中心开展的研究项目，提供 在各种样本类型上提供最先进的转录分析和数据挖掘功能。这个 中心将可以使用在过去7年中持续运行的设施。它有 受益于贝勒医疗保健系统的持续投资，并可供其支配 最先进的基因组分析仪器和IT基础设施。数据将在 在严格受控的实验室环境中提供高通量、高性价比的Illumina珠阵平台，以 确保最高的数据质量和重复性。其他转录特征分析技术也在 可通过此核心获得，例如实时聚合酶链式反应或纳米串平台。一组生物信息学家已经 已整合到核心，以开发和维护数据管理基础设施 构成其运作的中坚力量。自定义数据管理和挖掘解决方案可用于 对大量微阵列数据的优化利用。生物信息学和生物统计学支持也将 可供个别研究人员用于分析其微阵列结果。微阵列核心 At BUR在基因组学和免疫学领域之间开展了项目，并获得了 在特征分析方面的重要专门知识：a)各种疾病患者的血液；b)小细胞数量 从组织或细胞培养中分离出来；c)体外暴露于各种先天刺激下的血液；d)血液 在抗原肽的存在下培养的。 将为符合以下条件的临床试验的所有项目和机械部件提供支持 被求婚了。更具体地说，将在项目1的背景下生成体外血液档案 (Pascual)，而在培养中对抗原重新刺激的反应将在项目2的背景下进行概述 (上野)和试点项目(Chaussabel)。

The role of the genomics core is to support the research projects carried out by the center by providing state-of-the-art transcription profiling and data mining capabilities over a wide range of sample types. The center will have access to a facility that has been in continuous operation for the past 7 years. It has benefited from a continuous investment on the part of the Baylor Health Care System and has at its disposal state of the art genomic analysis instruments and IT infrastructure. Data will be generated on the high-through and cost-effective Illumina BeadArray platform in a strictly controlled laboratory environment to insure the highest data quality and reproducibility. Other transcriptional profiling technologies are also available through this core, such as real-time PCR or NanoString platforms. A team of bioinformaticians has been integrated to the core in order to develop and maintain the data management infrastructure that constitutes the backbone of its operation. Custom data management and mining solutions are available for the optimal exploitation of large volumes of microarray data. Bioinformatics and biostatistics support will also be made available to individual investigators for the analysis of their microarray results. The microarray core at BUR has carried out projects at the interface between the fields of genomics and immunology, and gained significant expertise in profiling: a) blood of patients with a wide range of diseases; b) small cell numbers isolated from tissues or cell cultures; c) blood exposed in vitro to a wide range of innate stimuli; and d) blood cultivated in the presence of antigenic peptides. Support will be provided across all the projects and mechanistic components of the clinical trials that are being proposed. More specifically, ex-vivo blood profiles will be generated in the context of project 1 (Pascual), while responses to antigen re-stimulation in culture will be profiled in the context of project 2 (Ueno) and the pilot project (Chaussabel).